Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after a treatment-free interval.

David Rosmarin, M.D., of the Indiana University School of Medicine in Indianapolis, and colleagues conducted a 48-week open-label, long-term extension study (ADORING 3) evaluating tapinarof in 728 ...

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Organon a déclaré mardi avoir acquis de Biogen les droits réglementaires et commerciaux de Tofidence pour perfusion ...

F RIDAY, March 14, 2025 (HealthDay News) -- Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days ...

If approved, tapinarof's main rival will be Amgen and its oral PDE4 inhibitor Otezla (apremilast) – acquired for $13.4 billion in 2019 in side deal to Bristol-Myers Squibb's $74 billion takeover ...

Shanghai Henlius Biotech, Inc. et Organon ont annoncé aujourd’hui que l’Agence européenne des médicaments a validé la demande ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

Organon has shared positive results from a long-term extension (LTE) study of its Vtama (tapinarof) cream, 1% in atopic dermatitis (AD) patients aged as young as two years. Findings from the phase 3 ...